Analyst Price Target is $2.63
▲ +154.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Soligenix in the last 3 months. The average price target is $2.63, with a high forecast of $3.75 and a low forecast of $1.50. The average price target represents a 154.85% upside from the last price of $1.03.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Soligenix. This rating has held steady since July 2021, when it changed from a Hold consensus rating.
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.